BRIEF: Zai Lab revenue falls on fading sales for its best-selling drug
Drug developer Zai Lab Ltd. (ZLB.US; 9688.HK) on Thursday reported its revenue fell 6% to $99.6 million in the first quarter from $106.5 million a year earlier, blaming a big…
Zai Lab under pressure over clinical results and rival drugs
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for…
FAST NEWS: Zai Lab’s loss narrows on improved drug sales
The Latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 33.7% to $80.3 million in the second quarter of this year. Looking Up: The company's net product revenue for…
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 24.5% to $335 million last year. Looking up: The narrower loss owed mainly to a 25% increase in revenue…
With no cure in sight, drugs firm LianBio begins exit strategy
The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four…
Everest reaches new heights on growing drug sales
The innovative drug maker said its revenue soared more than 850% last year to between 124 million yuan and 126 million yuan Key Takeaways: Everest Medicines’ revenue soared nine-fold last…
FAST NEWS: Zai Lab’s loss narrows on growing revenue
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier. Looking up: The…
Recent Articles
Zai Lab under pressure over clinical results and rival drugs
9688.HK
ZLAB.US
FAST NEWS: Zai Lab’s loss narrows on improved drug sales
9688.HK
ZLAB.US
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
9688.HK
ZLAB.US
FAST NEWS: Zai Lab’s loss narrows on growing revenue
ZLAB.US
9688.HK
RELATED ARTICLES
-
Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- A healthy return: drug spin-off nets Keymed up to $320 million
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
- Mega licensing deal lifts 3SBio profits but core sales slip
- Jacobio Pharma poised to turn a profit from precision cancer drugs
-
Joinn’s ‘jumping’ monkey market hides core weakness
6127.HK603127.SHG
